Predicting Relapse with Circulating Tumor DNA Analysis in Lung Cancer

Iñaki Comino-Mendez; Nicholas Turner

doi:10.1158/2159-8290.CD-17-1086

Predicting Relapse with Circulating Tumor DNA Analysis in Lung Cancer

Cancer Discov. 2017 Dec;7(12):1368-1370. doi: 10.1158/2159-8290.CD-17-1086.

Authors

Iñaki Comino-Mendez¹, Nicholas Turner^{2

3}

Affiliations

¹ Breast Cancer Now Research Centre, Institute of Cancer Research, London, United Kingdom.
² Breast Cancer Now Research Centre, Institute of Cancer Research, London, United Kingdom. Nick.Turner@icr.ac.uk.
³ Breast Unit, Royal Marsden Hospital, London, United Kingdom.

PMID: 29208774
DOI: 10.1158/2159-8290.CD-17-1086

Abstract

<b/> Advances in circulating tumor DNA (ctDNA) analysis are revealing new treatment strategies for patients with cancer. Detection of residual disease with ctDNA analysis predicts relapse with high accuracy after treatment for early-stage lung cancer. Cancer Discov; 7(12); 1368-70. ©2017 AACRSee related article by Chaudhuri et al., p. 1394.

Publication types

Comment

MeSH terms

Circulating Tumor DNA / genetics*
Humans
Lung Neoplasms / genetics*
Lung Neoplasms / pathology
Neoplasm Recurrence, Local

Substances

Circulating Tumor DNA